Drug Profile

Anti-CD99 antibody-conjugated doxorubicin liposomal nanoparticle - Nanovalent Pharmaceuticals

Alternative Names: CD99/Doxorubicin; NV-101- Nanovalent Pharmaceutical; NV101

Latest Information Update: 28 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NanoValent Pharmaceuticals
Class Anthracyclines; Antibodies; Antineoplastics; Doxorubicins; Drug conjugates; Immunoconjugates
Mechanism of Action Type II DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Sep 2024 No recent reports of development identified for preclinical development in Ewing's Sarcoma in USA
06 Aug 2020 NanoValent Pharmaceuticals licensed HPLN technology from Children's Hospital Los Angels
06 Aug 2020 Preclinical trials in Ewing's Sarcoma in USA (unspecified route) prior to August 2020 (Nanosmart Pharmaceutical website, August 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com